MTVA beat EPS expectations by 17.77%
Aug 15, 2025, 10:32 PM
0.00%
What does MTVA do
NeuroBo Pharmaceuticals, based in Cambridge, Massachusetts, develops multi-modal therapies, including DA-1241 for MASH and Type 2 Diabetes, and DA-1726 for obesity. The company went public on August 5, 2016.
NeuroBo Pharmaceuticals (MTVA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, NeuroBo Pharmaceuticals's actual EPS was -$0.26, beating the estimate of -$0.32 per share, resulting in a 17.77% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.